MAPS is currently seeking $9 million for European Medicines Agency (EMA) trials to supplement the data gathered for the FDA. MAPS will have a clearer estimate of costs for Phase 3 EMA trials after we complete our negotiations with EMA around the end of the Summer or Fall 2018 and with regulatory agencies in each country where we will have Phase 3 sites.
In June 2018, MAPS raised over $443,000 in new donations and pledges from 553 supporters.
We extend a special thanks to those who so generously supported MAPS last month:
General Support:
- Andre Ornish ($6,509)
- Mandy Gray ($5,000)
- Nicholas Maddix ($2,291)
- Grant Leonard ($1,100)
- Anonymous ($1,000)
- Sean Lawlor ($1,000)
Phase 3 MDMA/PTSD U.S.:
- David Rockefeller Estate Fund ($250,000)
- David Rockefeller Fund ($50,000)
- Anonymous ($30,399)
- Anonymous ($20,000)
- Michael Quattrone ($20,000)
- Candra Docherty ($1,500)
Phase 3 MDMA/PTSD Europe:
- Nicholas Reville ($24,892)
MDMA/PTSD Therapist Training:
- Kai Nygard ($5,153)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major non-family foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate
Learn how to include MAPS in your will or estate plans.
Learn more about hosting a Global Psychedelic Dinner to fundraise for MAPS.
